Attorney Docket No.: 4660.240-US PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE EXPRESS MAIL CERTIFICATE

Box Patent Application Commissioner for Patents Arlington, VA, 22202-3513

Re: U.S. Patent Application for

Title: Compounds With Growth Hormone Releasing

Applicants: Hansen et al

Sir:

Express Mail Label No. EI362579472US

Date of Deposit: February 5, 2002

I hereby certify that the following attached paper(s) or fee

- 1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
- 2. Patent Application
- 3. Copy of Executed Combined Declaration and Power of Attorney
- 4. Preliminary Amendment
- 5. Copy of Filing of Continued Prosecution Application (CPA) Under 37 C.F.R. §1.53(d) in duplicate

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, Arlington, VA 22202-3513.

> Sylvia Gonzalez (Name of person mailing paper(s) or fee) (Signature of person mailing paper(s) or fee)

Mailing Address: Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10017 (212) 867-0123



Attorney Docket No.: 4660.240-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application Commissioner for Patents 2900 Crystal Drive Arlington, VA. 22202-3513

Express Mail Label No. EI362579472US Date of Deposit February 5, 2002

Sir:

This is a request for filing a continuation application under 37 C.F.R. 1.53(b)

of

Applicant(s): Hansen et al

Title: Compounds With Growth Hormone Releasing Properties

525 pages of specification -0- sheets of Formal Drawings

3 sheets of Declaration and Power of Attorney

[x] The filing fee is calculated as follows:

Basic Fee: \$740.00

Total Claims: 1 - 20 = ? x 18 = \$-0-

Independent Claims: 1 - 3 = ? x 84 = \$-0-

Total Fee: \$740.00

Priority of Danish application nos. 1462/95, 0698/96, 0812/96 and 1248/96 filed on December 22, 1995, June 25, 1996, July 24, 1996 and November 6, 1996, respectively, is claimed under 35 U.S.C. 119.

Priority of U.S. provisional application no 60/022,062 filed on July 22, 1996 is claimed under 35 U.S.C. 119.

The benefit of application nos. 09/534.135 filed on March 23, 2000, 09/218.686 filed on December 21, 1998 and 08/769,020 filed December 18, 1996 in the U.S. is claimed under 35 U.S.C. 120.

Address all future communications to Reza Green, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$740, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: February 5, 2002

Respectfully submitted,

Cheryl H/Agris, Reg. No. 34,086 Outside Counsel for Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401 (212) 867-0123

23650
PATENT TRADEMARK OFFICE